Research
Daily Field Notes on emerging psychedelic clinical trials and pharmacology — N,N-DMT, 5-MeO-DMT, ayahuasca, ibogaine, and related tryptamines. Coverage of preprints, peer-reviewed papers from PubMed, and the major research centres (Imperial, MAPS, Beckley, Cybin, Usona). Receptor pharmacology, biased agonism, deuterated analogues, and the translation of psychedelic compounds from bench to clinic. Independent, evidence-led, primary sources cited.
Extended-state DMT infusion: three decades almost-but-not-quite attempted
There is something faintly poignant about the extended-state protocol's career: pharmacokinetically straightforward, clinically demanding, ethically complex, and philosophically loaded, all at once.
DMT in a Parkinson's model: Madrid group returns with fuller claims
The Madrid group — Morales-García, López-Moreno, Calleja-Conde, and colleagues — return to Experimental Neurology with what appears to be their most developed account yet of DMT's neuroprotective potential in a preclinical model of Parkinson's disease.
Strassman's IV DMT protocol: the dataset that still sets the dose
Rick Strassman's DMT studies were not the first to administer the compound to humans; that distinction belongs to the Hungarian chemist and psychiatrist Stephen Szára, who injected himself with it in 1956.
DMT on VTA Ih-negative neurons: sex-dependent firing changes in reward circuitry
A group at the University of Exeter has turned its electrodes on a rather specific neuronal population: the Ih-negative cells of the ventral tegmental area.
Manske to Szára: DMT's twenty-five years as a compound without a question
Manske's synthesis appeared in 1931, published in the Canadian Journal of Research, as part of a broader programme of work on tryptamine derivatives.
Lempel–Ziv complexity is the weakest correlate: Exeter's dose-dependent DMT EEG study
Lewis-Healey, Pallavicini, Cavanna and colleagues have now published, in the Journal of Cognitive Neuroscience, a dose-dependent EEG study of inhaled freebase DMT that carries a rather pointed conclusion:
DMT for Parkinson's: Sigma-1 Neuroprotection in a 6-OHDA Model
Calleja-Conde and Morales-García extend the Madrid group's DMT–sigma-1 neuroprotection case into a Parkinson's model. Suggestive, not yet definitive — but building.
DMT shows neuroprotective effects in a Parkinson's rat model — a Madrid group extends its σ1R hypothesis
Could DMT protect dopamine neurons? A new preclinical study from Madrid says yes — at least in rats. Here's what the data show, what the σ1R–NRF2 mechanism implies, and why translation to human Parkinson's remains an open question.
Ayahuasca Alkaloids in Hair: A New Long-Window Exposure Biomarker
Santos et al. validate a hair-analysis method for DMT and β-carbolines — turning a single strand into a months-long record of ayahuasca exposure.
Szára's 1956 self-experiment: the Budapest dose that launched DMT research
Cold War Hungary, 1956: Stephen Szára couldn't get LSD, so he made DMT and dosed himself. Modern psychedelic research began that afternoon.
Can Halogenated DMT Analogues Be Non-Hallucinogenic? G-Protein Bias
A preprint shows 2-chloro and 2-bromo DMT analogues display G-protein bias at 5-HT2A — relevant to the hunt for non-hallucinogenic psychedelics.
Long-Term Ayahuasca: Personality Shifts, Cognition Intact (Bouso)
Bouso compares chronic ayahuasca users with cannabis users and non-users: personality differs across groups, cognitive function is spared.